Brokerages Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) PT at $8.80

Key Points

• Inovio Pharmaceuticals has received a consensus rating of "Moderate Buy" from five analysts, with three recommending a buy and two suggesting a hold.
• The average one-year price target for Inovio's stock is $8.80, despite recent fluctuations in analyst price objectives.
• Institutional investors showed significant interest in Inovio, with Bank of America increasing its stake by 1,035.2% and multiple funds establishing new positions in the company.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the five ratings firms that are covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $8.80.

INO has been the topic of a number of recent analyst reports. Piper Sandler started coverage on Inovio Pharmaceuticals in a report on Wednesday, July 9th. They issued an "overweight" rating and a $5.00 price objective on the stock. Royal Bank Of Canada reaffirmed a "sector perform" rating and set a $5.00 price objective on shares of Inovio Pharmaceuticals in a report on Wednesday, May 14th. Oppenheimer dropped their target price on Inovio Pharmaceuticals from $15.00 to $13.00 and set an "outperform" rating on the stock in a report on Wednesday, May 14th. Finally, Wall Street Zen raised Inovio Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Friday, June 27th.

Inovio Pharmaceuticals Stock Down 1.7%

INO traded down $0.03 during trading on Friday, reaching $1.44. The company had a trading volume of 446,329 shares, compared to its average volume of 1,123,013. The stock has a market cap of $52.62 million, a P/E ratio of -0.45 and a beta of 1.38. The business has a 50 day simple moving average of $1.75 and a 200-day simple moving average of $1.86. Inovio Pharmaceuticals has a 52 week low of $1.30 and a 52 week high of $9.07.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, topping analysts' consensus estimates of ($0.74) by $0.23. The business had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.01 million. As a group, equities research analysts expect that Inovio Pharmaceuticals will post -4.23 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Nomura Holdings Inc. acquired a new stake in shares of Inovio Pharmaceuticals during the first quarter valued at approximately $28,000. Alpine Global Management LLC purchased a new stake in Inovio Pharmaceuticals in the 4th quarter worth about $31,000. Freedom Investment Management Inc. purchased a new stake in Inovio Pharmaceuticals in the 1st quarter worth about $31,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Inovio Pharmaceuticals by 39.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company's stock worth $34,000 after acquiring an additional 5,894 shares in the last quarter. Finally, Bank of Montreal Can purchased a new stake in Inovio Pharmaceuticals in the 4th quarter worth about $43,000. Institutional investors own 26.79% of the company's stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.